Dr. Plimack on Frontline Checkpoint Inhibitors in Bladder Cancer

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses checkpoint inhibitors in the frontline setting of bladder cancer.

There are currently 2 approved checkpoint inhibitors for the first-line treatment of patients with metastatic bladder cancer who are cisplatin ineligible—pembrolizumab (Keytruda) and atezolizumab (Tecentriq).

The results with either of these agents can be durable in this patient population, says Plimack, but there is currently no long-term follow-up data available.